Nguyen et al.[130] co‐cultured HUVEC cells, primary PBMCs, and cell lines replicating CAFs and breast cancer cells to recapitulate a complex HER2+ breast TME and characterise its responses to trastuzumab – a monoclonal antibody specifically used to treat HER2+ tumours. Here, ERBB2 is linked to breast carcinoma.